S66 — Star Combo Pharma Balance Sheet
0.000.00%
- AU$18.91m
- AU$5.09m
- AU$24.45m
Annual balance sheet for Star Combo Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | Interim Report | ARS |
| Standards: | AAS | AAS | AAS | AAS | AAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10.4 | 9.49 | 7.36 | 18.1 | 18 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.18 | 4.3 | 4.48 | 2.38 | 3.35 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 19.1 | 18.1 | 18.4 | 25.8 | 25.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 22.7 | 22.7 | 23.1 | 21.6 | 24 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 43.4 | 42.2 | 42.8 | 48.5 | 50.1 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4.01 | 4.33 | 4.87 | 5.86 | 6.53 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.04 | 9.13 | 9.49 | 10.4 | 11.3 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 35.4 | 33.1 | 33.3 | 38.1 | 38.8 |
| Total Liabilities & Shareholders' Equity | 43.4 | 42.2 | 42.8 | 48.5 | 50.1 |
| Total Common Shares Outstanding |